Geron says disciplined spending supports revenue growth and profitability path
Geron reports revenue up 24% year-to-date, citing disciplined spending and deeper community penetration, plus earlier-line patient use. International expansion and a myelofibrosis trial are flagged as near-term priorities toward profitability.
Revenue is up 24% year to date, with strong financial discipline and a clear path to profitability. The company said growth is being driven by deeper community penetration and earlier-line patient use, while international expansion and a pivotal myelofibrosis trial remain key near-term priorities.